ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,584.54
      -0.88%
      US Tech 100
      19,670.40
      -2.23%
      Dow Jones
      39,753.75
      0.08%
      Brent Oil
      85.06
      0.01%
      Bitcoin
      57,410.15
      -0.60%
      Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. AMEX
      6. Can Fite BioPharma Ltd (CANF)

      7. Can Fite BioPharma Ltd (CANF) News

      CANF

      Can Fite BioPharma (CANF)

      Can Fite BioPharma Ltd
      		Date:
      Sort by:
       Showing the most relevant articles for your search:AMEX:CANF
      DateTimeSourceHeadlineSymbolCompany
      12:21PMiHub NewswireFeaturedCannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing
      09/27/20237:00AMBusiness WireCan-Fite Novel Approach for the Treatment of Pancreatic Carcinoma with Namodenoson Receives Appreciation of the American Association of Cancer Research (AACR)AMEX:CANFCan Fite BioPharma Ltd
      09/13/202312:15AMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessAMEX:CANFCan Fite BioPharma Ltd
      09/11/202312:15AMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessAMEX:CANFCan Fite BioPharma Ltd
      09/07/20237:25AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
      09/07/20237:00AMBusiness WireCan-Fite to Share with Investors Latest Oncology and Rare Genetic Disease Developments at the H.C. Wainwright 25th Annual ConferenceAMEX:CANFCan Fite BioPharma Ltd
      09/01/20234:16PMEdgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementAMEX:CANFCan Fite BioPharma Ltd
      09/01/20234:15PMEdgar (US Regulatory)Form F-3 - Registration statement by foreign private issuersAMEX:CANFCan Fite BioPharma Ltd
      08/31/20237:12AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
      08/31/20237:00AMBusiness WireCan-Fite Reports Second Quarter 2023 Financial Results & Progress in Two Pivotal Phase III Clinical StudiesAMEX:CANFCan Fite BioPharma Ltd
      08/24/20237:19AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
      08/24/20237:10AMBusiness WireCan-Fite Enters Rare Genetic Disease Field Based on impactful findings of a Fondazione Telethon and Naples University Researcher showing Piclidenoson is efficacious in Treating Lowe SyndromeAMEX:CANFCan Fite BioPharma Ltd
      08/18/20237:06AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
      08/18/20237:00AMBusiness WireCan-Fite Submitted to FDA a Pediatric Plan to Allow Registration of Piclidenoson for the Treatment of Adolescents with PsoriasisAMEX:CANFCan Fite BioPharma Ltd
      08/07/20234:15PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
      07/31/20234:15PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
      07/17/20237:11AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
      07/17/20237:00AMBusiness WireCan-Fite: Granted Breakthrough Abstract Award for Namodenoson in Treatment of Advanced Liver Cancer by ASCO Conquer Cancer FoundationAMEX:CANFCan Fite BioPharma Ltd
      06/29/20237:11AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)AMEX:CANFCan Fite BioPharma Ltd
      06/29/20237:10AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
      06/29/20237:00AMBusiness WireCan-Fite Receives U.S. FDA’s Go Ahead for Piclidenoson Psoriasis Registration PlanAMEX:CANFCan Fite BioPharma Ltd
      06/13/202310:28AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)AMEX:CANFCan Fite BioPharma Ltd
      06/13/20237:00AMBusiness WireCan-Fite to Submit IND for the Treatment of Pancreatic Cancer Patients with NamodenosonAMEX:CANFCan Fite BioPharma Ltd
      06/02/20237:00AMBusiness WireCan-Fite to Participate in Out-licensing and Distribution Partnering Meetings at Bio International Convention in BostonAMEX:CANFCan Fite BioPharma Ltd
      06/01/20237:08AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)AMEX:CANFCan Fite BioPharma Ltd
      06/01/20237:00AMBusiness WireCan-Fite Reports First Quarter 2023 Financial Results & Provides Clinical UpdateAMEX:CANFCan Fite BioPharma Ltd
      05/30/20237:15AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)AMEX:CANFCan Fite BioPharma Ltd
      05/30/20237:00AMBusiness WireCan-Fite: Namodenoson’s Inhibition of Pancreatic Carcinoma Receives Recognition from the American Society of Clinical Oncology (ASCO)AMEX:CANFCan Fite BioPharma Ltd
      05/15/20237:00AMBusiness WireCan-Fite: Presenting Namodenoson’s New Pancreatic Cancer Indication to Potential Partners at BioEquity Europe 2023AMEX:CANFCan Fite BioPharma Ltd
      05/09/20237:08AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)AMEX:CANFCan Fite BioPharma Ltd
       Showing the most relevant articles for your search:AMEX:CANF